Live data · NADAC + Part D CY24 · reviewed daily

Oxybutynin (OXYTROL)

Cholinergic Muscarinic Antagonist class · 21 generic manufacturers · 39 ANDAs filed at FDA.

First FDA approval1990-09-30
Generic availableYes · 21 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$174.7M in CY2024 Part D spend8.1M claims · 2.6M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.033/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.046
Across all dosage forms in distribution.
Highest NADAC
$0.048
Range is tight.
Plans with PA
10 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Oxybutynin used for?

Oxybutynin is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Oxybutynin?

Yes. 39 ANDAs filed at FDA, 21 generic manufacturers currently shipping.

How much does my plan pay for Oxybutynin?

Across 329 Part D plans, Oxybutynin averages $0.046/unit (NADAC). Lowest available: $0.033/unit. Highest in distribution: $0.048/unit.

Is Oxybutynin on the FDA shortage list?

Oxybutynin has been discontinued by its manufacturer(s).

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.